Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items (2019 - 2025)

Historic Non-cash Items for BridgeBio Pharma (BBIO) over the last 7 years, with Q2 2025 value amounting to $10.9 million.

  • BridgeBio Pharma's Non-cash Items fell 8349.36% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 8349.36%. This contributed to the annual value of $78.8 million for FY2024, which is 79626.36% up from last year.
  • BridgeBio Pharma's Non-cash Items amounted to $10.9 million in Q2 2025, which was down 8349.36% from $10.3 million recorded in Q1 2025.
  • In the past 5 years, BridgeBio Pharma's Non-cash Items ranged from a high of $239.5 million in Q2 2021 and a low of $2.0 million during Q1 2021
  • Over the past 5 years, BridgeBio Pharma's median Non-cash Items value was $56.7 million (recorded in 2022), while the average stood at $61.3 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 9743.03% in 2022, then surged by 785164.74% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Non-cash Items (Quarter) stood at $10.1 million in 2021, then tumbled by 77.87% to $2.2 million in 2022, then skyrocketed by 7851.65% to $178.6 million in 2023, then crashed by 55.9% to $78.8 million in 2024, then crashed by 86.15% to $10.9 million in 2025.
  • Its Non-cash Items was $10.9 million in Q2 2025, compared to $10.3 million in Q1 2025 and $78.8 million in Q4 2024.